the prolia® patient
Prolia® (denosumab) for patients living with osteoporosis
People living with osteoporosis have an increased risk of fractures, particularly fractures of the spine, vertebrae, wrist, and femur. These fractures result in significant clinical and financial consequences for individuals and society. Treatment of osteoporosis patients aims to reduce the fracture risk that occur due to bone thinning and fragile bones, and Prolia® (denosumab) is a medication for osteoporosis that has been shown to reduce the risk of fractures of the spine as well as other fractures in postmenopausal women at increased risk of fracture.